- Details
- Phillip Koo and Daniel Saltzstein delve into the ECLIPSE clinical trial. The trial, aiming to enroll over 400 patients, brings Lutetium-177, a radioligand therapy, to patients with metastatic castrate-resistant prostate cancer at an earlier stage than it's currently approved for. Dr. Saltzstein outlines the trial's inclusion criteria, notably patients with castrated testosterone, PSA progression,...
|
- Details
- Alicia Morgans interviews Soumyajit Roy regarding his work on the COU-AA-302 data set, published in European Urology. The study investigates the effects of definitive prostate treatments, such as radiation therapy or radical prostatectomy, on outcomes when patients with metastatic castrate-resistant prostate cancer (mCRPC) are treated with abiraterone. Dr. Roy explains his motivation for the study...
|
- Details
- Elena Castro joins Alicia Morgans in a discussion on the clinical trial landscape for metastatic castration-resistant prostate cancer. When seeing a patient, Elena considers prior therapies and genetic testing, noting BRCA1 and BRCA2 alterations being investigated earlier provide an opportunity to treat patients with different PARP inhibitors. Drs. Morgans and Castro highlight the use of radiophar...
|
- Details
- Heather Cheng and Andrea Miyahira discuss the GENTleMEN study, which explored the feasibility of an internet-based, cost-free genetic testing program for men with metastatic prostate cancer. The study aimed to provide genetic testing to patients with advanced disease by removing barriers to access and cost and was launched in 2016 after research suggested that 25% of metastatic prostate cancer tum...
|
- Details
- Andrew Armstrong joins Andrea Miyahira in discussing a retrospective analysis of the prospective multicenter PROPHECY trial of men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide seeking to develop a liquid biopsy using circulating tumor cells (CTCs) that they can associate with outcomes in men with mCRPC and ultimately apply that to a PSMA-tar...
|
- Details
- Andrea Miyahira and Akash Patnaik discuss a Clinical Cancer Research publication that explores a new approach to disrupt immuno metabolic pathways within an aggressive variant form of prostate cancer. Dr. Patnaik provides background on the current state of metastatic castrate-resistant prostate cancer and the biologic underpinnings of aggressive variant prostate cancer, focusing on the PTEN PI3-ki...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with only one ARAT and are taxane-based chemo naive. The ECLIPSE trial is bei...
|
- Details
- Rahul Aggarwal joins Alica Morgans in conversation discussing a phase II study of patients with de novo small cell neuroendocrine prostate cancer, a high-risk group of patients with limited standard of care treatment options. The treatment was a combination immunotherapy trial, combining pembrolizumab, an immune checkpoint inhibitor, with BXCL 701, an investigational agent. The composite response...
|
- Details
- Alicia Morgans and Oliver Sartor discuss the latest developments and changes in the advanced prostate cancer landscape. Dr. Sartor mentions that novel hormones are used as first-line treatment in most cases and that the controversy around treating first-line metastatic CRPC is no longer relevant. He believes the evolution is going to continue with the novel hormones going earlier in different sett...
|
- Details
- Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial's primary endpoint was radio...
|
